INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE EVIDENCE INDEX

The Study Library.

4,771 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.

Showing studies that examined strawberries. Clear

2 studies

2012 / Prospective cohort study

Greater long-term intakes of blueberries and strawberries were linked to slower rates of cognitive decline in older women.

Researchers prospectively followed 16,010 women aged ≥70 years from the Nurses' Health Study, assessing cognitive function three times at 2-year intervals and averaging dietary data from 1980 through the initial cognitive interview. Greater intakes of blueberries (mean difference = 0.04, 95% CI = 0.01-0.07, p-trend = 0.014) and strawberries (mean difference = 0.03, 95% CI = 0.00-0.06, p-trend = 0.022) were associated with slower rates of cognitive decline in a global score comparing extreme intake categories. These estimates were equivalent to approximately 1.5 to 2.5 years of age. Greater intakes of anthocyanidins and total flavonoids were also linked to slower rates of cognitive decline (p-trends = 0.015 and 0.053, respectively).

Shows an association, not proof of cause and effect.

Devore EE, Kang JH, Breteler MM, et al. Ann Neurol, 2012. PMID 22535616

2012 / Narrative review

Plant polyphenols, including grape and blueberry juices, show potential in the treatment of cognitive impairment in preliminary human trials and rodent studies.

This review discusses the potential role of plant polyphenols and fruit products in treating age-related cognitive disorders and dementia. Blueberry, strawberry, blackberry, grape, and plum juices or extracts have been tested in cognitively impaired rodents, and small human trials have examined grape and blueberry juice. Specific polyphenols like resveratrol and pterostilbene have been studied or shown to improve cognition in rodents. Future human trials need to consider poor bioavailability, optimal timing of therapy, and the appropriate form of treatment.

Cherniack EP Br J Nutr, 2012. PMID 22475317